Evidence map›Paper›PMID 27338266›Full record

ArticleScientific reports2016

Transcriptome sequencing uncovers a three-long noncoding RNA signature in predicting breast cancer survival.

Wenna Guo, Qiang Wang, Yueping Zhan, Xijia Chen, Qi Yu, Jiawei Zhang, Yi Wang, Xin-Jian Xu, Liucun Zhu

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 83 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Wenna GuoSchool of Life Sciences, Shanghai University, Shanghai, 200444, P.R. China.
Qiang WangState Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, 210093, P.R. China.
Yueping ZhanSchool of Life Sciences, Shanghai University, Shanghai, 200444, P.R. China.
Xijia ChenSchool of Life Sciences, Shanghai University, Shanghai, 200444, P.R. China.
Qi YuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
Jiawei ZhangCollege of Information Science and Technology, Sanda University, Shanghai, 201207, P.R. China.
Yi WangSchool of Life Sciences, Shanghai University, Shanghai, 200444, P.R. China.
Xin-Jian XuDepartment of Mathematics, Shanghai University, Shanghai, 200444, P.R. China.
Liucun ZhuSchool of Life Sciences, Shanghai University, Shanghai, 200444, P.R. China.
Shanghai University · CNFudan University Shanghai Cancer Center · CNNanjing University · CNSanda University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long noncoding RNAs (lncRNAs) play a crucial role in tumorigenesis. The aim of this study is to identify lncRNA signature that can predict breast cancer patient survival. RNA expression data from 1064 patients were downloaded from The Cancer Genome Atlas project. Cox regression, Kaplan-Meier, and receiver operating characteristic (ROC) analyses were performed to construct a model for predicting the overall survival (OS) of patients and evaluate it. A model consisting of three lncRNA genes (CAT104, LINC01234, and STXBP5-AS1) was identified. The Kaplan-Meier analysis and ROC curves proved that the model could predict the prognostic survival with good sensitivity and specificity in both the validation set (AUC = 0.752, 95% confidence intervals (CI): 0.651-0.854) and the microarray dataset (AUC = 0.714, 95%CI: 0.615-0.814). Further study showed the three-lncRNA signature was not only pervasive in different breast cancer stages, subtypes and age groups, but also provides more accurate prognostic information than some widely known biomarkers. The results suggested that RNA-seq transcriptome profiling provides that the three-lncRNA signature is an independent prognostic biomarker, and have clinical significance. In addition, lncRNA, miRNA, and mRNA interaction network indicated lncRNAs may intervene in breast cancer pathogenesis by binding to miR-190b, acting as competing endogenous RNAs.

Indexed as

AdultAgedAged, 80 and overBase SequenceBiomarkers, TumorBreast NeoplasmsFemaleGene Expression ProfilingHumansMaleMicroRNAsMiddle AgedModels, TheoreticalPrognosisRNA, Long NoncodingSequence Analysis, RNABiomarkers, TumorMicroRNAsMIRN191 microRNA, humanRNA, Long Noncoding

Identifiers

PMID27338266
PMCPMC4919625
OpenAlexW2474773888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.